tocilizumab in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
Talaschian, 2021 1.56 [0.34; 7.13]
Veiga, 2021 2.70 [0.92; 7.92]
1.36 [0.54 ; 3.41 ] CORIMUNO-TOCI-ICU (Group 2), 2020, Talaschian, 2021, Veiga, 2021 3 45% 257 moderate not evaluable deathsdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
Talaschian, 2021 1.25 [0.30; 5.14]
Veiga, 2021 2.70 [0.92; 7.92]
0.93 [0.57 ; 1.50 ] CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, REMAP-CAP (tocilizumab), 2021, Talaschian, 2021, Veiga, 2021 5 36% 1,138 moderate not evaluable deaths (time to event analysis only)detailed results Talaschian, 2021 1.25 [0.30; 5.14]
1.25 [0.30 ; 5.14 ] Talaschian, 2021 1 0% 40 NA not evaluable clinical deteriorationdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
0.56 [0.26 ; 1.20 ] CORIMUNO-TOCI-1 (Group 1), 2020 1 0% 130 NA not evaluable clinical improvementdetailed results REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
1.64 [1.25 ; 2.15 ] REMAP-CAP (tocilizumab), 2021 1 0% 755 NA not evaluable death or ventilationdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
Veiga, 2021 1.54 [0.65; 3.63]
0.93 [0.35 ; 2.49 ] CORIMUNO-TOCI-1 (Group 1), 2020, Veiga, 2021 2 63% 260 moderate not evaluable recoverydetailed results Talaschian, 2021 0.64 [0.14; 2.92]
0.64 [0.14 ; 2.92 ] Talaschian, 2021 1 0% 36 NA not evaluable serious adverse eventsdetailed results Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
1.94 [0.74 ; 5.09 ] Talaschian, 2021, Veiga, 2021 2 0% 165 moderate not evaluable adverse eventsdetailed results Veiga, 2021 1.65 [0.81; 3.37]
1.65 [0.81 ; 3.37 ] Veiga, 2021 1 0% 129 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-06 08:06 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 395
- roots T: 290